CA2745436A1 - Antibody design using anti-lipid antibody crystal structures - Google Patents

Antibody design using anti-lipid antibody crystal structures Download PDF

Info

Publication number
CA2745436A1
CA2745436A1 CA2745436A CA2745436A CA2745436A1 CA 2745436 A1 CA2745436 A1 CA 2745436A1 CA 2745436 A CA2745436 A CA 2745436A CA 2745436 A CA2745436 A CA 2745436A CA 2745436 A1 CA2745436 A1 CA 2745436A1
Authority
CA
Canada
Prior art keywords
antibody
lipid
fragment
amino acid
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2745436A
Other languages
English (en)
French (fr)
Inventor
Roger A. Sabbadini
Jonathan Michael Wojciak
Tom Huxford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apollo Endosurgery Inc
Original Assignee
Apollo Endosurgery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apollo Endosurgery Inc filed Critical Apollo Endosurgery Inc
Publication of CA2745436A1 publication Critical patent/CA2745436A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2745436A 2008-12-05 2009-12-04 Antibody design using anti-lipid antibody crystal structures Abandoned CA2745436A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US12031808P 2008-12-05 2008-12-05
US61/120,318 2008-12-05
US15589509P 2009-02-26 2009-02-26
US61/155,895 2009-02-26
US23125809P 2009-08-04 2009-08-04
US61/231,258 2009-08-04
PCT/US2009/066862 WO2010065921A2 (en) 2008-12-05 2009-12-04 Antibody design using anti-lipid antibody crystal structures

Publications (1)

Publication Number Publication Date
CA2745436A1 true CA2745436A1 (en) 2010-06-10

Family

ID=42233904

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2745436A Abandoned CA2745436A1 (en) 2008-12-05 2009-12-04 Antibody design using anti-lipid antibody crystal structures

Country Status (9)

Country Link
US (1) US20110044990A1 (https=)
EP (1) EP2374001A4 (https=)
JP (1) JP2012511026A (https=)
KR (1) KR20110097923A (https=)
CN (1) CN102573905A (https=)
AU (1) AU2009322185A1 (https=)
CA (1) CA2745436A1 (https=)
IL (1) IL213358A0 (https=)
WO (1) WO2010065921A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011153416A2 (en) * 2010-06-04 2011-12-08 Lpath, Inc. Novel anti-s1p antibody variants of lt1009
ITRM20100441A1 (it) * 2010-08-05 2012-02-06 Michele Pitaro Procedimento per la produzione di anticorpi monoclonali anti-idiotipo ad uso diagnostico e/o terapeutico
KR102165384B1 (ko) * 2012-08-07 2020-10-16 메사추세츠 인스티튜트 오브 테크놀로지 항-뎅기 바이러스 항체 및 이들의 용도
AU2015217149B2 (en) 2014-02-11 2020-09-10 Massachusetts Institute Of Technology Novel full spectrum anti-dengue antibody
KR20170076756A (ko) 2014-10-30 2017-07-04 텍스타일-베이스드 딜리버리, 인코포레이티드 전달 시스템
CN110698560B (zh) * 2015-12-24 2021-11-26 凯惠科技发展(上海)有限公司 一种tpbg抗体及其制备方法、其偶联物和应用
US20190214108A1 (en) * 2016-09-16 2019-07-11 Osaka University Immunological entity clustering software
CN117050176A (zh) 2017-07-31 2023-11-14 豪夫迈·罗氏有限公司 基于三维结构的人源化方法
CN107480360B (zh) * 2017-08-03 2020-04-24 中北大学 光束细分和相界面漫反射的激光烧熔的数值计算方法
CN109837250B (zh) * 2019-01-15 2021-10-12 中国农业科学院兰州兽医研究所 羔羊睾丸支持细胞永生化细胞系及其建立方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5567610A (en) * 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
WO1988007089A1 (en) * 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5229275A (en) * 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5932448A (en) * 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5777085A (en) * 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
ATE244763T1 (de) * 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6129914A (en) * 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5573905A (en) * 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
GB9223377D0 (en) * 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
GB9325182D0 (en) * 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) * 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US5882644A (en) * 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
ES2375931T3 (es) * 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
WO1999045959A1 (en) * 1998-03-13 1999-09-16 Dana-Farber Cancer Institute, Inc. Humanized antibody and uses thereof
JP2002531466A (ja) * 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
CA2432978C (en) * 2000-12-22 2012-08-28 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
US7678386B2 (en) * 2002-07-15 2010-03-16 Board Of Regents The University Of Texas Liposomes coated with selected antibodies that bind to aminophospholipids
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2007038392A2 (en) * 2005-09-23 2007-04-05 Walter Reed Army Institute Of Research (Wrair) Antibodies with simultaneous subsite specificities to protein and lipid epitopes
US20080213274A1 (en) * 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
US8796429B2 (en) * 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
US20080138334A1 (en) * 2006-05-31 2008-06-12 Sabbadini Roger A Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same
US9274129B2 (en) * 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
EP2083862A4 (en) * 2006-10-27 2012-09-19 Lpath Inc COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES AND DISORDERS
BRPI0718118A2 (pt) * 2006-10-27 2017-05-30 Lpath Inc composições e métodos para ligação de sphingosine-1-fosfato

Also Published As

Publication number Publication date
KR20110097923A (ko) 2011-08-31
US20110044990A1 (en) 2011-02-24
EP2374001A4 (en) 2013-03-13
IL213358A0 (en) 2011-07-31
WO2010065921A2 (en) 2010-06-10
WO2010065921A3 (en) 2011-12-29
CN102573905A (zh) 2012-07-11
AU2009322185A1 (en) 2011-07-21
EP2374001A2 (en) 2011-10-12
JP2012511026A (ja) 2012-05-17

Similar Documents

Publication Publication Date Title
EP2400981A1 (en) Humanized platelet activating factor antibody design using anti-lipid antibody templates
AU2022201163B2 (en) Complement factor D antagonist antibodies and conjugates thereof
CA2745436A1 (en) Antibody design using anti-lipid antibody crystal structures
US11440954B2 (en) Optimized anti-TL1A antibodies
AU2016332900B2 (en) ASGR inhibitors
US8026342B2 (en) Compositions and methods for binding sphingosine-1-phosphate
CN101687031B (zh) 用于治疗眼疾和眼病的组合物及方法
MX2010008578A (es) Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
US11104722B2 (en) Immunogenetic restriction on elicitation of antibodies
US20130261287A1 (en) Antibody design using anti-lipid antibody crystal structures
US20140186339A1 (en) Compositions and methods for treating ocular diseases and conditions
US20260109754A1 (en) Sars-cov-2 antibodies and methods of using the same
WO2011156242A2 (en) Improved anti-lysophospholipid antibody design using antibody structures
WO2011153416A2 (en) Novel anti-s1p antibody variants of lt1009

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20160715